System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print 1 citation

PubMed: 42533268 DOI: 10.1111/dom.71103

Economic Burden of Type 1 Diabetes in France.

Diabetes Obes Metab

Authors: Emmanuel Cosson, Corinne Emery, Elodie Torreton, Bruno Detournay, Bruno Verges, Pierre-Yves Benhamou, Maxime Brule, Laura Sablone, Guy Fagherazzi, Jean Pierre Riveline

Affiliations

  • Department of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CSO-IdF Nord, Bobigny, France.
  • Center of Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Bobigny, France.
  • Cemka, Bourg-la-Reine, France.
  • Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France.
  • INSERM LNC-UMR1231, University of Burgundy, Dijon, France.
  • Department of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France.
  • Francophone Foundation for Diabetes Research, Paris, France.
  • Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.
  • Department of Diabetology and Endocrinology, Lariboisiere Hospital, AP-HP, Paris, France.
  • INSERM U1138 Immunity and Metabolism in Diabetes, ImMeDiab Team, Necker Enfants Malades Institute, Paris Cité University, Paris, France.

Abstract

AIM

To estimate the societal costs of Type 1 diabetes (T1D) in France, including direct and indirect costs.

MATERIALS AND METHODS

We conducted a descriptive retrospective cross-sectional study on all adult patients (aged 18 and over) with T1D identified in the SFDT1 cohort and compared them to a matched cohort of patients without diabetes considering age, gender, deprivation status and geographical area. An Insurance claim data analysis was conducted for the year 2023 individually and then extrapolated to all of France. Costs were broken down by expense categories and insulin delivery devices.

RESULTS

The average individual societal cost of T1D in France in 2023 compared with the absence of diabetes was estimated at €9940 (€9340 when considering direct costs only). Nearly half of the identified costs were attributable to the use of medical devices. An analysis stratifying patients by treatment modality (closed-loop, pump or multiple daily injections) highlighted the significant costs associated with the use of the most advanced technologies for delivering insulin (average costs were respectively €13 557, €11 062, and €7004, respectively). The total cost of T1D in France was estimated at between €1.59 and €1.79 billion in 2023 excluding undiagnosed cases and premature mortality associated with the disease.

CONCLUSIONS

Our results suggest that the most advanced insulin delivery devices have a significant short-term economic impact. Although this paper does not cover the research, model-based studies do suggest that there are some advantages to using such devices, including potential future savings due to lower complication rates.

MeSH

Diabetes Mellitus, Financial Stress, Insulin, Diabetes Mellitus, Type 1